A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP ...

Schomburg said Eisbach views EIS-12656 as an alternative to poly-ADP-ribose polymerase inhibitors (PARP) inhibitors in therapy for many hard-to-treat cancers. PARP proteins are involved in DNA repair, ...

[48–50] Final data remain to be published. Table 1. Poly-(ADP-ribose) polymerase inhibitors in clinical studies. PARP inhibitor Number of completed or ongoing studies Type of studies completed ...

College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao 266042, China ...

AstraZeneca and Merck & Co’s – known as MSD outside the US and Canada – olaparib already holds approvals to treat certain cases of prostate cancer under the brand name Lynparza. PARP inhibitors such ...

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for some years, but would-be competitors continue to chip away at its market share.

Daiichi Sankyo has claimed approval in Japan, its home market, for TROP2-targeting antibody-drug conjugate (ADC) datopotamab ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. Days after Merck & Co. posted a disappointing result on patient survival from its PD-1/PARP combination of Keytruda and Lynparza ...

However, PARPi monotherapy should not be used for such patients at this time. Niraparib, a potent inhibitor of PARP-1 and PARP-2, is US Food and Drug Administration (FDA)–approved for the maintenance ...

"The OlympiA trial examines adding one year of the oral PARP inhibitor olaparib after completion of standard treatment for higher risk breast cancer in individuals with pathogenic germline BRCA ...